Clinical Trial Update: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of gemtuzumab ozogamicin and gilteritinib in adults with relapsed/refractory FLT3-mutant acute myeloid leukemia. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Gilteritinib (gilteritinib)

Snippet

Sponsor: Centre Antoine Lacassagne | Conditions: AML, Leukaemia (Acute Myeloid) | Phase 2 | Status: ACTIVE_NOT_RECRUITING